Edition:
United Kingdom

Sientra Inc (SIEN.OQ)

SIEN.OQ on NASDAQ Stock Exchange Global Select Market

24.09USD
17 Oct 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$24.09
Open
$23.77
Day's High
$24.17
Day's Low
$23.18
Volume
45,285
Avg. Vol
119,337
52-wk High
$26.79
52-wk Low
$8.79

Chart for

About

Sientra, Inc. is a medical aesthetics company. The Company's primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast... (more)

Overall

Beta: --
Market Cap(Mil.): $307.56
Shares Outstanding(Mil.): 19.31
Dividend: --
Yield (%): --

Financials

  SIEN.OQ Industry Sector
P/E (TTM): -- 32.37 33.73
EPS (TTM): -2.66 -- --
ROI: -61.89 14.01 14.31
ROE: -64.43 16.77 16.04

SEC sues U.S. breast-implant company's ex-CEO after stock dive

The U.S. Securities and Exchange Commission on Wednesday sued the founder and former chief executive of Sientra Inc for fraudulently concealing problems with his company's breast and other implants as it was raising $61.4 million in a public stock offering.

19 Sep 2018

UPDATE 1-SEC sues U.S. breast-implant company's ex-CEO after stock dive

Sept 19 The U.S. Securities and Exchange Commission on Wednesday sued the founder and former chief executive of Sientra Inc for fraudulently concealing problems with his company's breast and other implants as it was raising $61.4 million in a public stock offering.

19 Sep 2018

SEC sues ex-CEO of California breast implant company after stock nosedived

Sept 19 The U.S. Securities and Exchange Commission on Wednesday sued the founder and former chief executive of Sientra Inc for fraudulently concealing problems with his company's breast and other implants as it was raising $61.4 million in a public stock offering.

19 Sep 2018

BRIEF-Sientra Q1 Loss Per Share $0.99

* Q1 EARNINGS PER SHARE VIEW $-0.84 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

09 May 2018

BRIEF-Sientra Inc. Announces Closing Of $115 Mln Public Offering Of Common Stock

* SIENTRA, INC. ANNOUNCES CLOSING OF $115 MILLION PUBLIC OFFERING OF COMMON STOCK AND EXERCISE IN FULL OF UNDERWRITERS’ OVER-ALLOTMENT OPTION Source text for Eikon: Further company coverage:

07 May 2018

BRIEF-Sientra Announces Pricing Of Upsized Public Offering Of Common Stock

* SIENTRA ANNOUNCES PRICING OF UPSIZED PUBLIC OFFERING OF COMMON STOCK

03 May 2018

BRIEF-Sientra Inc Says Commenced Underwritten Public Follow-On Offering Of About $75 Mln Of Its Stock To Be Sold By Co

* SIENTRA INC - COMMENCED UNDERWRITTEN PUBLIC FOLLOW-ON OFFERING OF ABOUT $75 MILLION OF ITS STOCK TO BE SOLD BY COMPANY

30 Apr 2018

BRIEF-Sientra Sees Preliminary Unaudited Net Sales For Q1 2018 Of About $14.5 Mln

* SIENTRA INC - SEES PRELIMINARY UNAUDITED NET SALES FOR Q1 2018 OF ABOUT $14.5 MILLION

25 Apr 2018

BRIEF-Sientra Receives FDA Approval Of PMA Supplement

* SIENTRA INC - ADDITIONAL $10 MILLION OF EXISTING CREDIT FACILITY NOW ACCESSIBLE WITH FDA APPROVAL

18 Apr 2018

Competitors

  Price Chg
Allergan plc (AGN.N) $191.00 +3.01
Johnson & Johnson (JNJ.N) $139.46 +2.90

Earnings vs. Estimates